Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Author:
Funder
National Cancer Institute
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference47 articles.
1. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab;Topalian;JAMA Oncol,2019
2. Five-year outcomes with Pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J Clin Oncol,2021
3. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC ITX Resistance Taskforce;Kluger;J Immunother Cancer,2020
4. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer;Shah;Oncotarget,2018
5. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies;Walsh;Ther Adv Med Oncol,2020
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer;Frontiers in Oncology;2023-11-09
2. Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer;Pharmacological Research;2023-10
3. Advancing Understanding of Non-Small Cell Lung Cancer with Multiplexed Antibody-Based Spatial Imaging Technologies;Cancers;2023-09-29
4. Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors;Cancers;2023-09-08
5. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer;Cancer Research Communications;2023-08-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3